Patents by Inventor Phillip Patrick Sharp

Phillip Patrick Sharp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PLASMA KALLIKREIN INHIBITORS
    Publication number: 20240025917
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.
    Type: Application
    Filed: November 18, 2021
    Publication date: January 25, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Jianming Bao, Natalija Cernaka, Alan C. Cheng, Ying-Duo Gao, Salman Jabri, Jovan Alexander Lopez, Rohan Merchant, Anthony Ken Ogawa, Skylar K. Osler, Christopher J. Sinz, Phillip Patrick Sharp, Haiqun Tang, Maoqun Tian, Dong Xiao, Song Yang
  • PLASMA KALLIKREIN INHIBITORS
    Publication number: 20230348428
    Abstract: The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.
    Type: Application
    Filed: July 6, 2021
    Publication date: November 2, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Jacqueline D. HICKS, Rongze Kuang, Christopher J. Sinz, Matthew J. Lombardo, Jovan Alexander Lopez, Rohan Rajiv Merchant, Phillip Patrick Sharp, Zhicai Wu, Zhiqiang Zhao, Alan C. Cheng, Song Yang, Jianming Bao, Maoqun Tian, Galen Paul Shearn-Nance
  • CDP protein secretion inhibitors
    Patent number: 11339193
    Abstract: Provided herein are compounds that inhibit protein secretion, e.g., via inhibition of Sec61. Also provided are compositions of the inhibitor compounds, and methods of using these inhibitors. The compounds disclosed herein can be used, e.g., for the treatment of cancer, arthritis, and/or inflammation.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: May 24, 2022
    Assignees: KEZAR LIFE SCIENCES, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Dustin McMinn, John William Taunton, Phillip Patrick Sharp
  • CDP PROTEIN SECRETION INHIBITORS
    Publication number: 20210017233
    Abstract: Provided herein are compounds that inhibit protein secretion, e.g., via inhibition of Sec61. Also provided are compositions of the inhibitor compounds, and methods of using these inhibitors. The compounds disclosed herein can be used, e.g., for the treatment of cancer, arthritis, and/or inflammation.
    Type: Application
    Filed: March 29, 2019
    Publication date: January 21, 2021
    Inventors: Dustin McMinn, John William Taunton, Phillip Patrick Sharp
  • Benzodiazepines as bromodomain inhibitors
    Patent number: 10167292
    Abstract: The present invention provides novel benzodiazepine derivatives of Formula I or pharmaceutically acceptable derivatives, polymorphs, salts or prodrugs thereof. Said compounds have potential as bromodomain (BRD) inhibitors.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: January 1, 2019
    Assignee: Catalyst Therapeutics Pty Ltd.
    Inventors: Chris Burns, Jean-Marc Garnier, Phillip Patrick Sharp, John Feutrill, Anthony Cuzzupe
  • Benzodiazepines as bromodomain inhibitors
    Publication number: 20180230153
    Abstract: The present invention provides novel benzodiazepine derivatives of Formula I or pharmaceutically acceptable derivatives, polymorphs, salts or prodrugs thereof. Said compounds have potential as bromodomain (BRD) inhibitors.
    Type: Application
    Filed: August 4, 2016
    Publication date: August 16, 2018
    Inventors: Chris Burns, Jean-Marc Garnier, Phillip Patrick Sharp, John Feutrill, Anthony Cuzzupe